

# 1 **Epigenetic Reprogramming Mediates Monocyte and Heterologous** 2 **T Cell-derived Cytokine Responses after BCG Vaccination**

3 Cancan Qi<sup>1,2,3,†</sup>, Zhaoli Liu<sup>1,2,†</sup>, Gizem Kilic<sup>4</sup>, Andrei S. Sarlea<sup>4</sup>, Priya A. Debisarun,<sup>4</sup> Xuan  
4 Liu,<sup>1,2</sup> Yonatan Ayalew Mekonnen,<sup>1,2,5</sup> Wenchao Li,<sup>1,2</sup> Martin Grasshoff,<sup>1,2</sup> Ahmed  
5 Alaswad,<sup>1,2</sup> Apostolos Petkoglou,<sup>1,2</sup> Valerie A.C.M. Koeken,<sup>1,2,4,6</sup> Simone J.C.F.M. Moorlag<sup>4</sup>,  
6 L. Charlotte J. de Bree<sup>4</sup>, Vera P. Mourits<sup>4</sup>, Leo A.B. Joosten,<sup>4,7</sup> Yang Li,<sup>1,2,4,‡</sup> Mihai G.  
7 Netea,<sup>4,8,‡</sup> and Cheng-Jian Xu<sup>1,2,4,‡\*</sup>

8

9 <sup>1</sup>Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz  
10 Centre for Infection Research (HZI) and Hannover Medical School (MHH). Hannover,  
11 Germany

12 <sup>2</sup>TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI)  
13 and the Hannover Medical School (MHH), Hannover, Germany

14 <sup>3</sup>Microbiome Medicine Center, Division of Laboratory Medicine, Zhujiang Hospital,  
15 Southern Medical University, Guangzhou, Guangdong, China

16 <sup>4</sup>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud  
17 University Medical Center, Nijmegen, the Netherlands

18 <sup>5</sup>Institute for Bioinformatics, University Medicine Greifswald, Greifswald, Germany

19 <sup>6</sup>Research Centre Innovations in Care, Rotterdam University of Applied Sciences, Rotterdam,  
20 the Netherlands

21 <sup>7</sup>Department of Medical Genetics, Iuliu Hațieganu University of Medicine and Pharmacy,  
22 Cluj-Napoca, Romania

23 <sup>8</sup>Department of Immunology and Metabolism, Life and Medical Sciences Institute (LIMES),  
24 University of Bonn, Bonn, Germany

25

26 †These authors contributed equally and share the first authorship

27 ‡These authors contributed equally and share the last authorship

28

29 \*Correspondence: [Xu.Chengjian@mh-hannover.de](mailto:Xu.Chengjian@mh-hannover.de)

30

31 Cheng-Jian Xu, PhD

32 Centre for Individualised Infection Medicine (CiiM), Hannover Medical School

33 Tel: +49 511 2200 2 7175

34 Email: [Xu.Chengjian@mh-hannover.de](mailto:Xu.Chengjian@mh-hannover.de)

35

36

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

37 **Abstract**

38

39 Epigenetic reprogramming plays an important role in shaping immune memory traits within  
40 both innate (trained immunity) and adaptive immune cells following Bacillus Calmette-Guérin  
41 (BCG) vaccination. However, the precise impact of dynamic DNA methylation alterations on  
42 immunological responses after BCG vaccination remains inadequately elucidated. To address  
43 this knowledge gap, we conducted a comprehensive study by integrating longitudinal analysis  
44 and systems biology approaches. We established a cohort of 284 healthy Dutch individuals,  
45 capturing data on genetics, cytokine responses to *ex vivo* stimulation and genome-wide DNA  
46 methylation at baseline, as well as at 14 days and 90 days after BCG vaccination. Our findings  
47 revealed distinct patterns of DNA methylation alternations in the short- and long-term  
48 following BCG vaccination. Moreover, we established that baseline DNA methylation profiles  
49 exert influence on the change in interferon- $\gamma$  (IFN- $\gamma$ ) production upon heterologous  
50 (*Staphylococcus aureus*) stimulation before and after BCG vaccination. Specifically, we  
51 identified the regulation of kisspeptin as a novel pathway implicated in the modulation of IFN-  
52  $\gamma$  production, and this finding has been substantiated through experiment validation. We also  
53 observed associations between BCG-induced DNA methylation changes and increased IFN- $\gamma$   
54 and Interleukin-1  $\beta$  (IL-1 $\beta$ ) production upon *S. aureus* stimulation. Interestingly, by integrating  
55 with genetic, epigenetic, and cytokine response data from the same individuals, mediation  
56 analysis demonstrated that most of the identified DNA methylation changes played a mediating  
57 role between genetic variants and cytokine responses, for example, the changes of cg21375332  
58 near *SLC12A3* gene mediated the regulation of genetic variants on IFN- $\gamma$  changes after BCG  
59 vaccination. Sex-specific effects consistently manifested in DNA methylation changes after  
60 BCG vaccination and in the association between baseline methylation and cytokine responses.  
61 Together, our findings provide deeper insights into immune response mechanisms, crucial for  
62 developing effective epigenetic-based medical interventions for personalized medicine.

63

64 **Keywords:** *BCG vaccination, cytokines response, trained immunity, DNA methylation, systems*  
65 *biology*

66

67

68

## 69 **Introduction**

70 Host immune responses are traditionally classified into innate and adaptive, with only the latter  
71 initially thought to have the ability to develop immunological memory. However, in recent  
72 years, a growing body of evidence has shown that innate immunity can also exhibit memory  
73 characteristics<sup>1</sup>. Studies have shown explicitly that *Bacillus Calmette-Guérin* (BCG)  
74 vaccination can induce innate immune memory through epigenetic reprogramming of myeloid  
75 cells and their bone marrow progenitors<sup>2–6</sup>. This non-specific innate immune memory can  
76 provide cross-protection against unrelated-pathogen and is referred to as “trained immunity”  
77 <sup>7,8</sup>. In addition, BCG vaccination induces classical adaptive immune memory, with T-cell-  
78 derived IFN- $\gamma$  responses being relevant for protection against tuberculosis<sup>2</sup>.

79  
80 A distinguishing feature of the trained innate immune cells is their ability to mount a stronger  
81 transcriptional response compared to naïve cells when challenged with a pathogen. Recent  
82 research has identified various factors that can influence the induction of trained immunity,  
83 such as circulating inflammatory proteins<sup>9</sup>, metabolites<sup>10</sup> and the transcriptomic profiles of  
84 immune cells<sup>11–13</sup>, and the gut microbiome<sup>14</sup>. Studies have shown that after being vaccinated  
85 with BCG, systematic inflammation is reduced at both the protein and transcription levels  
86 <sup>9,11,12,15</sup>. Additionally, the production of cytokine following BCG vaccination is associated with  
87 the abundance of microbial genomes, which in turn influences circulating metabolites<sup>14</sup>.

88  
89 One of the key molecular mechanisms involved in the induction of trained immunity is the  
90 epigenetic reprogramming of immune cells. Chromatin accessibility and histone marks have  
91 been the mechanisms most studied in this regard<sup>7,16</sup>. Another important mechanism for  
92 epigenetic gene transcription regulation is through modulation of DNA methylation. Previous  
93 studies have demonstrated the association of DNA methylation with infection and immune  
94 memory<sup>17,18</sup>, showing how infection-induced changes in DNA methylation regulate the  
95 transcriptional response to infection and contribute to short-term memory in innate immune  
96 cells<sup>17</sup>. Demethylation of enhancer elements mediated by transcription factors (TFs) binding  
97 may allow for a faster response to a secondary infection and thus plays a crucial role in innate  
98 immune memory<sup>19</sup>. More recently, studies have shown that BCG vaccination leads to changes  
99 in DNA methylation<sup>20</sup> in monocytes and T cells of children<sup>21</sup>. We have previously suggested  
100 that DNA methylation changes after BCG vaccination in adults as well<sup>22</sup>, but a comprehensive  
101 analysis of the impact of DNA methylation on innate immune memory is missing. To better

102 understand the molecular basis of trained immunity, we investigated whether DNA methylation  
103 plays an important role in this process.

104

105 In this study, we hypothesize that *in vivo* BCG vaccination induces changes in DNA  
106 methylation associated with a trained immunity response. To test this hypothesis, we  
107 longitudinally assessed *ex vivo* cytokine production upon *Staphylococcus aureus* stimulation,  
108 and genome-wide DNA methylation at baseline, 14 days, and 90 days after BCG vaccination  
109 in a cohort of 303 healthy volunteers from the Human Functional Genomics Project (300BCG  
110 cohort, [www.humanfunctionalgenomics.org](http://www.humanfunctionalgenomics.org)). We assessed the dynamic changes in DNA  
111 methylation following BCG vaccination and their association with cytokine responses using  
112 integrative system biological approach. We further validated our findings in an independent  
113 cohort (BCG booster trial <sup>23</sup>) and a number of the identified pathways in *in-vitro* experiments.

114

## 115 **Results**

### 116 **Study design and global DNA methylation variability**

117 This study was conducted in the 300BCG cohort, and the details of the cohort have been  
118 previously reported<sup>9</sup>. In brief, 303 healthy volunteers received BCG vaccination and whole  
119 blood samples were collected before (T0), 14 days (T14), and 3 months (T90) after vaccination.  
120 The genome-wide DNA methylation profiles were then measured on high-quality DNA  
121 isolated from the whole blood using Illumina Epic arrays. Additionally, the production of  
122 cytokines (IL-1 $\beta$ , IL-6, TNF- $\alpha$ , IFN- $\gamma$ ) from peripheral blood mononuclear cells (PBMCs) was  
123 measured after stimulation with *Staphylococcus aureus* at T0 and T90. The fold change (FC)  
124 of cytokine production between T90 and T0, referred to as trained immunity markers in this  
125 study, was used as a measure of BCG-induced trained immune response. Plasma inflammatory  
126 protein concentrations were also obtained at three time points (Figure 1A). After rigorous  
127 quality control, downstream analyses included 284 subjects, consisting of 126 males and 158  
128 females. The mean age was 25 years (ranging from 18 to 71), with a mean BMI of 22.48 kg/m<sup>2</sup>  
129 (Table S1). Epigenome-wide association studies (EWAS) were performed on 751,564 high-  
130 quality probes from the three different time points of these 284 subjects. The EWAS aimed to  
131 examine: 1) the epigenetic modifications induced by BCG vaccination, and 2) the association  
132 between DNA methylation and changes of *ex vivo* cytokine production capacity induced by  
133 vaccination (Figure 1B).

134

135 The univariate associations between the principal components (PCs) calculated from the whole  
136 blood DNA methylation data at each time point, covariates and estimated cell proportions<sup>24</sup> are  
137 depicted in Figure 1C and S1. The first 30 PCs accounted for 35% of the total variation in the  
138 blood methylome at T0. The strongest associations were observed between the cell proportions,  
139 particularly neutrophils, and the top two DNA methylation PCs. The first DNA methylation  
140 PC was also associated with batch effects (sample plate), while age, sex, smoking behavior,  
141 and body mass index (BMI) showed no significant correlations with the top two PCs.

142

### 143 **BCG vaccination induced changes in DNA methylation**

144 The changes in DNA methylation over time after BCG vaccination were assessed using a  
145 mixed effects model that accounted for age, sex, batch effect and estimated cell proportions as  
146 covariates, with sample ID as a random effect. In total, we identified 11 CpG sites that were  
147 significantly (false discovery rate (FDR) < 0.05) changed following BCG vaccination (Figure  
148 2A, Table S2). Among these, five CpG sites showed increased methylation, while six CpG  
149 sites displayed decreased methylation 90 days after vaccination. Notably, the changes observed  
150 at T14-T0 for eight out of the 11 CpG sites were converse to those observed at T90-T0 (Figure  
151 2B). This observation potentially indicates the presence of distinct epigenetic mechanisms  
152 during different time intervals after BCG vaccination. To verify this finding, we further  
153 checked the 73 CpG sites with suggestive significance ( $P < 1 \times 10^{-5}$ ), and identified consistent  
154 patterns (Figure 2C). Pathway analysis of the genes annotated to the 11 CpG sites revealed  
155 enrichment in pathways related to Human papillomavirus infections, VEGFA-VEGFR2  
156 signaling and tight junction, which were reported to be related to the immune response to  
157 infections previously<sup>25,26</sup> (Figure S2A).

158

159 We next checked the association between the identified CpG sites and other traits using the  
160 EWAS catalog (<http://www.ewascatalog.org>) (Table S3). Five out of the 11 CpG sites have  
161 been previously associated with age. Two of these sites were reported to be associated with  
162 proteins that involved in B cell development. For instance, cg06221058 (mapped to gene  
163 *MYH9*) was reported to be associated with age and IGMH (Immunoglobulin heavy constant  
164 Mu) protein levels. cg06013215 (mapped to gene *PTGER4*) was reported to be related to  
165 protein amounts of IGLL1 (Immunoglobulin lambda-like polypeptide 1) and FCER2 (Fc  
166 Epsilon Receptor II).

167

168 Considering the cell-type specificity of DNA methylation markers, the methylation level of  
169 these 11 significant CpG sites was then correlated with the estimated cell proportions at each  
170 time point (Figure S2B). At all three time points, a strong correlation pattern was observed  
171 between the CpG sites and estimated neutrophil proportion, and consistent patterns were  
172 identified when correlating the CpG sites with cell counts of neutrophil subtypes measured by  
173 flow cytometry (Figure S2C). The top correlated neutrophil subtypes included CD10+ CD66b,  
174 CD10+ CD62L, and PDL1-CD62LP neutrophils.

175

### 176 **BCG vaccination induced short-term and long-term changes in DNA methylation**

177 As shown in Figure 2 B-C, the observed patterns of DNA methylation changes suggested the  
178 involvement of distinct epigenetic mechanisms in the short- and long-term effects following  
179 BCG vaccination. To gain further insights into these effects, we compared the DNA  
180 methylation changes between day14 and day0 (T14-T0), day90 and day0 (T90-T0), as well as  
181 day90 and day14 (T90-T14) respectively, using mixed effects models. Three CpG sites from  
182 the T14-T0 model, five from the T90-T0 model, and sixty-four from the T90-T14 model were  
183 identified with genome-wide significant changes (FDR<0.05). In order to capture the overall  
184 dynamics of DNA methylation after BCG vaccination, CpG sites reaching suggestive  
185 significance threshold ( $P < 1 \times 10^{-5}$ ) were also included in the downstream analysis (Table S4-  
186 S6).

187

188 In the T14-T0 model, which represents the short-term effect of BCG vaccination on methylome,  
189 we identified 39 CpG sites ( $P < 1 \times 10^{-5}$ ). Among these, 14 CpG sites exhibited decreased  
190 methylation at T14 compared to T0, while 25 CpG sites showed increased methylation.  
191 Notably, all of these sites demonstrated an opposite direction of change when comparing T90-  
192 T14 (Figure 2D, Figure S3A). This suggests that the later time period, from T14 to T90, might  
193 represent a recovery phase following BCG vaccination. Using functional enrichment tools  
194 experimentally derived Functional element Overlap analysis of ReGions from  
195 EWAS(eFORGE)<sup>27</sup>, we found that the demethylated CpG sites were enriched in active  
196 transcription states, and the gene mapped to these sites were enriched in pathways involved in  
197 the metabolism of RNA, indicating an active transcriptional activity of the demethylated sites  
198 at T14. In contrast, the methylated CpG sites were enriched in an inactive transcription state,  
199 and were involved in pathways related to integrin signaling and platelet activation and  
200 aggregation (Figure 2D, Figure S4D). These results suggested that the short-term DNA



201 methylation alterations induced by BCG vaccination may be involved in the regulation of  
202 transcription activity and may return to their original levels over time.

203

204 The long-term effect model, T90-T0, revealed 17 methylated CpG sites and 19 demethylated  
205 CpG sites ( $P < 1 \times 10^{-5}$ , Figure 2E, Figure S3B) associated with BCG vaccine. These methylated  
206 CpG sites exhibited enrichment in both active and inactive transcription states, and the genes  
207 mapped to these CpG sites were enriched in pathways such as tight junction and bacterial and  
208 viral infection (Figure 2E, Figure S4E). This suggests that the persistent long-term effect of  
209 BCG on epigenetics may be related to the response to pathogenic infection. The persistent  
210 effect of BCG vaccination on epigenetics at 90 days post-vaccination reflects a lasting  
211 epigenetic memory. Interestingly, the majority of the increased CpG sites (64.7%) first slightly  
212 decreased at T14 and then increased at T90, indicating that the majority of the increased  
213 changes at T90 actually occurred after T14 (Figure 2E, Figure S3B). These results suggested a  
214 “late” epigenetic effect of vaccination, in contrast to the “immediate” transcriptional effect of  
215 vaccination<sup>13</sup>.

216

217 To gain a deeper understanding of the “late” effect of BCG vaccination, we conducted a  
218 comparison of methylation profiles between T90 and T14. Through this analysis, we identified  
219 115 CpG sites that displayed suggestively significant changes ( $P < 1 \times 10^{-5}$ ). Among these, 58  
220 CpG sites showed increased methylation at T90 compared to T14 after initially being  
221 demethylated at T14, surpassing even the levels observed at T0. In contrast, the demethylated  
222 CpG sites exhibited the opposite pattern of methylation changes (Figure 2F, Figure S3C). The  
223 genes mapped to the identified CpG sites were enriched in pathways related to active  
224 transcription state, inflammatory response (e.g., ISG15 antiviral mechanism, antiviral  
225 mechanism by IFN-stimulated genes, and CD163 mediated anti-inflammatory) and nervous  
226 system (e.g., renin secretion and neurotrophin signaling) (Figure 2F, Figure S4F). Interestingly,  
227 we found that the methylated CpG sites identified from comparison of T90 vs T14 were  
228 enriched in hypo-methylated sites, while the demethylated CpG sites were enriched in  
229 hypermethylated sites (Fisher’s exact test,  $P = 8.31 \times 10^{-6}$ , Figure 2G, Figure S4C), aligning with  
230 the concept of epigenetic aging drift<sup>28</sup>. However, the increased CpG sites identified from the  
231 T14 vs T0 comparison model were enriched in hyper-methylated sites, contrasting with the  
232 pattern observed in comparison of T90 vs T14 (Figure S4 A-B).

233

234 **BCG-induced DNA methylation changes were associated with the alteration of plasma**  
235 **inflammatory proteins**

236 We previously reported that BCG vaccination reduced circulating inflammatory markers at  
237 both 14 days and 90 days after vaccination<sup>9</sup>. Given the significant changes in DNA methylation  
238 profiles upon BCG vaccination observed in this study and that the enriched pathways were  
239 related to immune responses to infections, we further investigated whether BCG-induced DNA  
240 methylation changes were associated with the altered concentration of circulating  
241 inflammatory proteins. In our group's previous findings, we identified 24 proteins exhibiting  
242 significant short-term decreases and 10 proteins that exhibited long-term decreases after BCG  
243 vaccination<sup>9</sup>. We correlated these proteins with CpG sites identified in T14 vs T0 (No. CpG  
244 =39) and T90 vs T0 (No. CpG = 36) comparison, respectively. We found that the DNA  
245 methylation changes in four CpG sites identified from T14 vs T0 comparison were significantly  
246 associated with alterations in two proteins upon BCG vaccination, with FDR<0.05 (Table S7).  
247 Specifically, two CpG sites were associated with CD6 (cg26624673 near gene *ADHFE1* and  
248 *MYBL1*, and cg10813029 near gene *TGIF1* and *DLGAP1*), and two were associated with OPG  
249 (cg20782252 near gene *MAD1L1* and *ELFNI*, and cg12598528 near gene *KCNT2*). In addition,  
250 we identified 77 CpG-protein pairs that reached nominal significance ( $P<0.05$ ), among which  
251 we observed a consistent pattern in which the CpG sites exhibiting increased methylation at  
252 T14 in comparison to T0 were inversely correlated with proteins that exhibited a decrease at  
253 T14 relative to T0 (Figure S5A). However, the CpG sites identified from the comparison of  
254 T90 vs T0 didn't show any significant association with protein abundance ( $FDR < 0.05$ , Table  
255 S7, Figure S5B). These results indicate that BCG-induced DNA methylation changes are  
256 associated with reduced concentrations of inflammatory proteins in the circulation, particularly  
257 regarding DNA methylation changes from T0 to T14. This suggests that short-term DNA  
258 methylation changes may play a role in regulating the reduction of circulating inflammatory  
259 proteins induced by BCG vaccination.

260

261 **Baseline epigenetic profiles were associated with the trained immunity responses after**  
262 **BCG vaccination**

263 Next, we tested if the epigenetic profiles at baseline were associated with trained immunity (TI)  
264 responses, which were defined as the fold changes of cytokine productions stimulated with *S.*  
265 *aureus* at T90 compared to T0 (Figure 1). We measured both the monocyte-derived cytokines  
266 (IL-1 $\beta$ , IL-6, and TNF- $\alpha$ ), and IFN- $\gamma$ , which represents the lymphoid cellular response. Our  
267 results revealed that 41 CpG sites at baseline were significantly associated with the increased



268 IFN- $\gamma$  production capacity at T90 compared to T0, denoted as TI (IFN- $\gamma$ ) (FDR<0.05, Figure  
269 3A, Table S8). The strongest association was observed at cg16685860 ( $P=6.02\times 10^{-10}$ ), located  
270 near gene *PLD2*. We identified 22 out of 41 CpG sites that were positively associated with TI  
271 (IFN- $\gamma$ ). The genes mapped to these sites were enriched in pathways including phospholipases,  
272 Kisspeptin receptor system, and LPA receptor mediated events. Conversely, 19 out of the 41  
273 sites were negatively associated with TI (IFN- $\gamma$ ), and the genes mapped to these sites were  
274 enriched in the apoptosis pathway and FAS pathway, which was also related to programmed  
275 cell death (Figure S6A). We did not find any significant associations between baseline DNA  
276 methylation and TI (IL-1 $\beta$ ) or TI (TNF- $\alpha$ ), except for one CpG site (cg07586956, mapped to  
277 *PCBP1* and *C2orf42* genes) that showed an association with TI (IL-6) ( $P=5.40\times 10^{-10}$ ).  
278 Furthermore, we assessed the association between DNA methylation at 14 and 90 days after  
279 BCG vaccination and TI (Table S10-S11). We found a total of 9 CpG sites at T14 and 95 CpG  
280 sites at T90 were linked to TI (IFN- $\gamma$ ) (Table S10). For TI (IL-1 $\beta$ ), we identified 32 CpG sites  
281 at T14 and only three CpG sites at T90 (Table S11), showing different patterns compared to  
282 the analysis of TI (IFN- $\gamma$ ), where more sites were identified at T90.

283  
284 We further checked the association of the identified CpG sites with other traits by utilizing the  
285 EWAS catalog (Table S9). Among the 41 CpG sites, 18 were previously found to be associated  
286 with age (Figure S6B). Interestingly, we discovered that five CpG sites (cg03433260 near gene  
287 *BID*, cg09391860 near gene *ZNF335* and *MMP9*, cg18591181 near gene *NIMIK*, cg25937862  
288 near gene *MRC2*, and cg22032521 near gene *HYLS1*) showed associations with five protein  
289 levels (EBAG9, GZMK, HAPLN4, LYN, and OSM) that have been previously reported in  
290 blood.

291  
292 Then, we investigated how much variance in TI (IFN- $\gamma$ ) could be explained by different omics  
293 layers, including polygenetic risk score (PRS)<sup>29</sup>, inflammatory proteins, metabolites, and DNA  
294 methylation. Comparing age, sex, and PRS and baseline inflammatory proteins, we discovered  
295 that baseline DNA methylation explained the largest proportion of variance of TI (IFN- $\gamma$ ),  
296 followed by the baseline metabolites (Figure 3B). A combined model of all data layers  
297 explained 56.1% variance for TI (IFN- $\gamma$ ). Further randomization tests confirm the significance  
298 of the finding ( $P$  value <0.001) (Fig S6D). We also checked if SNPs located proximal to the  
299 CpG sites associated with TI (IFN- $\gamma$ ) were enriched in cytokine-QTL of IFN- $\gamma$ , but we did not  
300 identify any significant enrichment (Table S12, Figure S6C).

301

### 302 **Kisspeptin modulates IFN $\gamma$ production capacity**

303 DNA methylation in the kisspeptin receptor system has been identified to influence IFN- $\gamma$   
304 responsiveness after BCG vaccination in this study. Kisspeptins are proteins encoded by the  
305 *KISS1* gene that have been initially described to inhibit metastases in cancer and induce  
306 secretion of gonadotropin-releasing hormone (GnRH), but recently an increasing role in  
307 immunomodulatory effects have been described<sup>30</sup>. To functionally validate whether  
308 kisspeptins modulate IFN- $\gamma$  production, human peripheral blood mononuclear cells were  
309 incubated for one hour with various concentrations of recombinant kisspeptin-10 (from 1 ng/ml  
310 to 100 ng/ml), followed by stimulation with either heat-killed *C. albicans* or *S. aureus* for 7  
311 days. Kisspeptin significantly inhibited IFN- $\gamma$  production capacity, validating its  
312 immunomodulatory role (Figure 3C). In contrast, no effects on IL-17 and IL-22 production,  
313 another two cytokines produced by T-cells, were observed (not shown). This demonstrates the  
314 inhibitory effect of kisspeptin on IFN- $\gamma$  production and argues that DNA methylation of *KISS1*  
315 likely impacts interferon production.

316

### 317 **BCG-induced DNA methylation changes were associated with *ex vivo* cytokine 318 production changes**

319 In order to investigate if the BCG-induced DNA methylation changes are associated with  
320 cytokine production changes, we further performed association analyses between Trained  
321 immunity and the differences of DNA methylation levels (DNAm-C) between any two time  
322 points (T14-T0, T90-T0, and T90-T14, Table S13). Notably, T90-T0 DNAm-C showed a  
323 significant association with trained immunity for all four traits, with the following numbers of  
324 significant associations, TNF N=2, IFN- $\gamma$  N=28, IL-1 $\beta$  N=14 and IL-6 N=3 (FDR<0.05, Figure  
325 S7A). This indicates that BCG-induced long-term DNA methylation changes were associated  
326 with *ex vivo* cytokine production changes. To better understand the roles of the trained  
327 immunity related DNAm-C of T90-T0, we performed the pathway enrichment analyses of the  
328 genes mapped to CpG sites with a P value lower than  $1 \times 10^{-5}$  (Figure S8). The trained immunity  
329 response as assessed by IL-1 $\beta$  production against a heterologous stimulus from the model T90-  
330 T0 was associated with enrichment in changes in DNA methylation for genes involved in  
331 Kinesins and Golgi-to-ER retrograde traffic. Kinesins are motor proteins that ensure the  
332 transport of cellular cargo, with an emerging role in supporting immune processes as well<sup>31,32</sup>.  
333 On the other hand, changes in IFN- $\gamma$  heterologous production were enriched in changes in DNA

334 methylation of genes involved in the mTOR signaling pathway (well-known to be involved in  
335 T-cell activation and trained immunity<sup>33,34</sup>), the VEGFA-VEGFR2 signaling pathway and  
336 other immune related pathways (e.g., IL-2 family signaling and IL-18 signaling pathways).  
337 These findings provide a further understanding of the functional implications of the DNAm-C  
338 in relation to cytokine production changes.

339

340 Interestingly, we observed that some of the CpG sites from the association model between  
341 Trained immunity and DNAm-C (T90-T0) (TNF- $\alpha$  N=11, IFN- $\gamma$  N=7, IL-1 $\beta$  N=7, and IL-6  
342 N=5, Figure S7C) exhibited significant changes upon BCG vaccination (P value <0.05).  
343 However, the CpG sites from the association analyses between Trained immunity and DNAm-  
344 C (T14-T0) or (T90-T14) did not show significant changes upon BCG vaccination. These  
345 findings suggest that the BCG-induced long-term DNA methylation changes, rather than short-  
346 term changes, may be involved in *ex-vivo* cytokine production alteration. Furthermore, it  
347 indicates that the development of immune-related epigenetic memory relies on long-term  
348 epigenetic changes. We also observed that TI (IFN- $\gamma$ )-C was associated with both baseline  
349 DNA methylation and DNAm-C of T90-T0 with a higher number of identified CpG sites  
350 compared to other cytokines. This finding is consistent with previous findings that reported  
351 enrichment of genes near CpG sites with long-term BCG effect in IFN related pathways<sup>20</sup>.

352

### 353 **Bidirectional causality between DNA methylation changes and *ex-vivo* cytokine** 354 **production changes**

355 The underlying causality of the significant association between trained immunity and DNAm-  
356 C remains unknown. To investigate this, we utilized the genotype data from 300BCG to infer  
357 a potential *in silico* causal relationship between trained immunity and DNA methylation  
358 changes (T90-T0) through mediation analysis<sup>35</sup>. We initially identified SNP – trained immunity  
359 - DNAm-C groups that exhibited significant association between every two variables and  
360 subsequently conducted bidirectional mediation analysis. In the mediation analysis of  
361 Direction1, we hypothesized the effects of SNPs on trained immunity were mediated by  
362 DNAm-C, and treated DNAm-C as mediator and trained immunity as outcomes. In the analysis  
363 of Direction2, trained immunity was treated as the mediator and DNAm-C as outcome (Figure  
364 4A). The majority of significant mediation results were identified for TI(IFN- $\gamma$ ). Specifically,  
365 seven CpG sites showed unidirectional causal relationships in Direction1 ( $P_{\text{Direction1}} < 0.05$  and  
366  $P_{\text{Direction2}} > 0.05$ ), two CpG sites of unidirectional causal relationships in Direction2  
367 ( $P_{\text{Direction2}} < 0.05$  and  $P_{\text{Direction1}} > 0.05$ ), and six CpG sites with bidirectional causal relationships

368 ( $P_{\text{mediation}} < 0.05$ , Figure 4B, Table S14). In addition, we also identified two CpG sites that  
369 mediated the effect of genetic variants on IL-1 $\beta$  changes (Direction1), along with four with  
370 bidirectional causal relationships, but none of the CpG sites were significant in Direction2  
371 (Figure 4B, Table S14).

372

373 This approach revealed a total of 18 unidirectional mediation linkages: Direction1 analysis  
374 (DNAm-C mediated) identified 11 significant linkages involving 9 CpG sites and two  
375 cytokines (IFN- $\gamma$  and IL-1 $\beta$ ) (Figure 4C), on the other hand, Direction2 analysis (trained  
376 immunity mediated) revealed 7 significant linkages consisted of three CpG sites and two  
377 cytokines (IFN- $\gamma$  and TNF- $\alpha$ ). More linkages and CpG sites were identified from Direction1,  
378 particularly for IFN- $\gamma$  and IL-1 $\beta$ , indicating the important role of persistent epigenetic  
379 modifications in regulating changes in both monocytes and T-cell derived cytokine production.  
380 For instance, cg25926804, located near the *TMEM75* and *GSDMC* gene, mediated 28.6% of  
381 the effect of rs6991078 on TI(IFN- $\gamma$ ) (Figure 4D). *GSDMC* was reported to be involved in  
382 defense response to bacterium previously<sup>36,37</sup>. Similarly, cg21375332 (near *SLC12A3* and  
383 *NUP93*), mediated 32.7% of the effect of rs604639 on IFN- $\gamma$  changes (Figure 4E). *SLC12A3*  
384 is a receptor for the pro-inflammatory cytokine IL-18, and was reported to contribute to IL-18-  
385 induced cytokine production, including IFN- $\gamma$ , IL-6, IL-18 and CCL2<sup>38</sup>. Interestingly, we also  
386 found cg19226099, located in *MC3R*, to act as a mediator for IFN- $\gamma$  (Figure 4F). *MC3R* is the  
387 receptor for melanocyte-stimulating hormone (MSH) and adrenocorticotrophic hormone  
388 (ACTH) was reported to be related to a delay in the age of puberty onset<sup>39</sup>, suggesting the  
389 importance of DNA methylation changes in genes related to hormone that mediating the effect  
390 of cytokine production changes after BCG vaccination. In the results from Direction2, where  
391 the trained immunity was treated as a mediator, few results were identified compared to  
392 Direction1, including cg07420470, located near *RAB3GAP2*, was mediated by TI (IFN- $\gamma$ )  
393 (Figure S9). *RAB3GAP2* is involved in the regulated exocytosis of neurotransmitters and  
394 hormones<sup>40</sup>.

395

### 396 **Sex-specificity of BCG effect on DNA methylation and the relationship between DNA** 397 **methylation and immune responses**

398 In a previous study<sup>9</sup>, sex-specificity in BCG-induced inflammatory protein changes was  
399 observed, indicating that the BCG vaccination might act differently in men and women. To  
400 further investigate this phenomenon, we stratified our samples by sex and assessed the short-  
401 and long-term changes separately in males and females, utilizing the same model as in the

402 previous analysis. Our analysis revealed that following BCG vaccination, there were  
403 suggestive significant short-term changes in 18 CpG sites among males, and 31 CpG sites  
404 among females ( $P < 1 \times 10^{-5}$ , Table S15) without any overlap, and most of the identified CpG  
405 sites show different direction of changes indicating a strong sex-specificity (Figure 5A-B).  
406 Specifically, at T14 compared to T0, we observed 13 demethylated sites (72.2%) in males and  
407 10 demethylated sites (32.3%) in females. Through enrichment analysis, we identified sex-  
408 specific pathways associated with these methylation changes. Among females, the sex-  
409 hormone related pathway GnRH secretion (also modulated by kisspeptins, see above)  
410 displayed significant involvement, while among males, functions related to the nervous system,  
411 including neurotransmitter receptors and postsynaptic signal transmission, GABA receptor  
412 activation, and Renin secretion, were found to be prominent. Additionally, we identified a few  
413 shared pathways between both sexes, such as those related to potassium channels (pathway  
414 potassium channels in females, and pathway G protein gated potassium channels and Inwardly  
415 rectifying K<sup>+</sup> channels in males) (Figure 5E).

416  
417 We also identified suggestive significant changes in 42 CpG sites in males, and 25 CpG sites  
418 in females as long-term effects after vaccination ( $P < 1 \times 10^{-5}$ , Figure 5C-D, Table S16). Unlike  
419 the short-term BCG effect sites, the long-term changes in CpG sites exhibited the most  
420 consistent increases or decreases in males, whereas no consistent patterns were identified in  
421 females (Figure S10). Pathway analysis revealed that the CpG sites showing long-term effects  
422 in males were enriched in functions related to infection and immune responses (host–pathogen  
423 interaction of human coronaviruses and Toll–like Receptor pathways) and cell death  
424 (nanoparticle triggered regulated necrosis). In contrast, the long-term sites in females were  
425 enriched in pathways including RUNX3 regulates NOTCH signaling, dopaminergic  
426 neurogenesis, and osteoblast differentiation (Figure 5F). These findings indicate that after BCG  
427 vaccination, the DNA methylation profiles undergo different trajectories in males and females,  
428 and these BCG-induced methylation changes are associated with distinct functional pathways.  
429 In summary, the short-term changes in methylation following BCG vaccination were enriched  
430 to functions related to sex hormones in females and the nervous system in males, while the  
431 long-term changes were associated with pathways related to pathogenic immune responses in  
432 males and the nervous systems in females.

433

434 The *ex vivo* cytokine production changes were reported to be associated with inflammatory  
435 proteins in a sex-dependent manner<sup>9</sup>. We also observed the sex-specific association between  
436 trained immunity of four cytokines and baseline epigenetic profiles by sex-stratified analysis,  
437 with a stronger association identified in males than females for all four cytokines tested in this  
438 study. In males, we identified 3579 CpG sites at baseline that were significantly associated  
439 with TI (IFN- $\gamma$ ) males, whereas only 584 sites showed significant association in females,  
440 without any overlap (FDR<0.05, Figure 5G, Table S17). Furthermore, the direction of 1883  
441 out of the total 4161 (45.3%) associations was inconsistent between males and females (Figure  
442 5H). Similar trends were observed for other cytokine markers, such as IL-1 $\beta$  (1107 in males  
443 and 62 in females), IL-6 (853 in males and 67 in females), and TNF- $\alpha$  (513 in males and 9 in  
444 females) (Table S18). Importantly, these associated sites were not enriched to the CpG sites  
445 that were significantly associated with sex at baseline (Fisher's exact test  $P > 0.05$ , Table S19).  
446 Instead, pathway analysis revealed that CpG sites associated with TI (IFN- $\gamma$ ) in both males and  
447 females were enriched in signal transduction pathways. However, other enriched pathways  
448 were specific to males or females. For instance, the top pathways in males included signaling  
449 by receptor tyrosine kinases, the Rap1 signaling pathway, and pathways in cancer, while in  
450 females, the top pathways were the Hippo signaling pathway, dopaminergic neurogenesis, and  
451 NrCAM interactions (Figure S11). To gain insight into the sex specificity of these associations,  
452 we also associated the identified CpG sites with five types of sex hormones including  
453 androstenedione, cortisol, 11 deoxy cortisol, 17 hydroxy progesterone, and testosterone.  
454 Interestingly, 10 CpG sites associated with TI (IFN- $\gamma$ ) in females were strongly associated with  
455 cortisol, and two CpG sites were also associated with 11 deoxy cortisol (spearman correlation  
456 FDR <0.05, Figure 5I), while for the sites identified in males, we did not identify any  
457 significant links with sex-hormones.

458

### 459 **Replication of EWAS results**

460 We conducted a replication study to validate our findings using an independent cohort. In this  
461 study, 17 individuals were vaccinated with BCG, and blood samples were collected before  
462 vaccination (T0) and 3 months (T90) after vaccination followed by DNA methylation profiling.  
463 The assessment of *ex vivo* cytokine changes followed was the same protocol as the discovery  
464 cohort. Firstly, we compared the difference of DNA methylation levels of 36 CpG ( $P < 1 \times 10^{-5}$   
465 in the discovery cohort) between T90 and T0 in the replication cohort, and we identified that  
466 21 out of 36 CpG sites showed the same direction, and two out of the 21 CpG sites showed



467 nominal significance ( $P < 0.05$ ) (Table S20). Due to the limited number of male samples  
468 collected available ( $N=4$ ), we were only able to test the female-specific results. We tested the  
469 long-term female specific CpG sites ( $N=25$ ), and 12 out of 25 CpG sites showed consistent  
470 directions of changes with one CpG site reaching nominal significance ( $P < 0.05$ , Table S21).

471  
472 Next, we replicated the associations between baseline DNA methylation and TI (IFN- $\gamma$ ), using  
473 the same model used in the discovery cohort. Out of 40 CpG sites, we identified five CpG sites  
474 that could be replicated with nominal significance ( $P < 0.05$ ) and consistent direction of effect  
475 (Table S22). Additionally, for the female-specific associations, we found that 34 out of 582  
476 CpG sites can be replicated with nominal significance ( $P < 0.05$ ) and consistent directions of  
477 effect. Among these, 10 CpG sites reached the FDR significance ( $FDR < 0.05$ , Table S23).

478

479

## 480 **Discussion**

481 Epigenetic reprogramming has been proposed as a mechanism underlying BCG-induced innate  
482 immune memory. In this study, we provide evidence for the dynamic landscape of DNA  
483 methylation changes following BCG vaccination and elucidate the role of DNA methylation in  
484 immunological responses induced by BCG vaccination. Our findings demonstrate that BCG  
485 induces persistent immune-related DNA methylation changes for up to at least 3 months, likely  
486 reflecting epigenetic memory at the DNA methylation level (Figure 6).

487

488 While long-term epigenetic processes have been proposed earlier to mediate trained immunity,  
489 most studies to date have investigated histone modifications<sup>41,42</sup>. A recent study investigated  
490 changes in DNA methylation in monocytes of young children<sup>20</sup>, while we suggested that DNA  
491 methylation changes after BCG vaccination in adults as well<sup>22</sup>. A comprehensive analysis of  
492 the impact of DNA methylation on innate immune memory in adults was missing. In this study,  
493 we observed distinct patterns of short- and long-term DNA methylation changes following  
494 BCG vaccination. Previous research has outlined distinct stages of epigenetic reprogramming  
495 in the induction of trained immunity, involving acute stimulation of innate immune cells  
496 leading to active transcription of proinflammatory factors, followed by a resting stage, where  
497 epigenomic changes are partially reversed after stimulus cessation<sup>43</sup>. In our study, we observed  
498 similar acute effects on DNA methylation at day 14 that returned back to baseline by day 90  
499 following BCG vaccination. Notably, the demethylated CpG sites associated with this acute  
500 effect were enriched in an active transcription state, consistent with the previous finding that

501 BCG vaccination induced acute and resting stages. Besides, persistent epigenetic changes,  
502 potentially contributing to epigenetic memory, were enriched in infection-related pathways and  
503 associated with *ex vivo* cytokine changes that represented innate immune memory. These  
504 findings suggest that epigenetic memory partly underlies the induction of immune memory.  
505 Furthermore, we identified a “late” epigenetic reprogramming that includes decreased  
506 hypermethylation and increased hypomethylation. DNA methylation is a known stable  
507 biomarker of aging, with a tendency towards increased hypermethylation in aging processes<sup>44</sup>.  
508 Interestingly, our results suggest that the “late” effect of BCG vaccination opposes the DNA  
509 methylation changes associated with natural aging, indicating a distinct epigenetic influence of  
510 BCG vaccination.

511  
512 BCG vaccination has been shown to induce epigenetic reprogramming, such as DNA  
513 methylation<sup>45</sup> and histone modifications<sup>2</sup>, which play a critical role in trained immunity or  
514 immunological memory. In our study, we investigated the association between DNA  
515 methylation levels and immunological memory following BCG vaccination, specifically  
516 focusing on *ex vivo* cytokine production changes of four cytokines upon *S. aureus* stimulation.  
517 We found that baseline DNA methylation explained a significant proportion of variance of T-  
518 cell heterologous IFN- $\gamma$  responses and this may also play a role in the process of immune  
519 memory<sup>46</sup>. These results indicated that individual differences in long-term innate immune  
520 effects induced by vaccines depend on intrinsic DNA methylation levels prior to vaccination,  
521 and DNA methylation status at certain CpG sites may facilitate the immune responses after  
522 BCG vaccination. Among the pathways modulated by DNA methylation that was found to  
523 strongly modulate heterologous immune responses, we identified baseline CpG sites enriched  
524 in the kisspeptin pathway. Kisspeptins are peptides that induce the release of GnRH, but with  
525 an increasing number of studies showing immunomodulatory effects<sup>47,48</sup>. Indeed, functional  
526 validation experiments demonstrate their modulatory effects on IFN $\gamma$  production,  
527 strengthening the hypothesis of their impact on long-term immune responses.

528  
529 Moreover, we identified that BCG-induced DNA methylation changes at day 90 compared to  
530 baseline, and these were associated with *ex vivo* cytokine changes including both IFN- $\gamma$  and  
531 IL-1 $\beta$ , representing responses from both monocytes and T-cell derived cytokine responses.  
532 Previous studies have shown that the stimulation of innate immune cells can leave an  
533 “epigenetic scar”, making the cells more responsive to a different stimulation<sup>43</sup>. Our results

534 suggest that epigenetic memory is represented by a combination of innate immune training and  
535 adaptive immune memory<sup>13,49</sup>. Furthermore, through mediation analysis, we showed the  
536 potential *in-silico* causal relationship between BCG induced persistent methylation changes  
537 and trained immunity. We identified more CpG sites that may mediate the regulation of genetic  
538 variants on IFN- $\gamma$  and IL-1 $\beta$  changes after BCG vaccination, suggesting the DNA methylation  
539 acts as a modulator of immune response. The identified CpG sites were located in genes related  
540 to pathogenic responses and cytokine productions, which stressed the importance of epigenetic  
541 reprogramming at CpG sites on the regulation of trained immunity. For example, the DNA  
542 methylation changes of cg21375332 near *SLC12A3* gene mediated the regulation of genetic  
543 variants on IFN- $\gamma$  changes, and this was consistent with previous study that *SLC12A3* was  
544 involved in IL-18-induced IFN- $\gamma$  production<sup>38</sup>. We also revealed that CpG site near *GSDMC*,  
545 a gene involved in the defense response to bacterium, mediated the changes of IFN- $\gamma$  after BCG  
546 vaccination.

547  
548 Several studies have demonstrated that the BCG vaccination can exhibit sex-specific  
549 effects<sup>50,51</sup>. In a study investigating the protective effects of neonatal BCG vaccination, it was  
550 observed that boys exhibited strong protective effects within the first week after vaccination,  
551 which diminished thereafter. Conversely, girls showed weaker protection initially but  
552 demonstrated stronger effects later on<sup>51</sup>. In our study involving adult participants, we also  
553 identified sex-specific DNA methylation changes induced by BCG vaccination, both in the  
554 short and long term. Short-term DNA methylation changes in females were enriched to the  
555 GnRH pathway, which influences hormone secretion and immune system development<sup>52</sup>.  
556 Long-term effects in males involved DNA methylation changes related to Toll-like receptors  
557 (TLRs), particularly TLR4, which recognizes bacteria lipopolysaccharide (LPS) and activates  
558 innate immunity. Conversely, long-term effects in females were observed in CpG sites  
559 associated with neuronal functions, including Notch signaling and dopaminergic neurogenesis.  
560 It is worth noting that the neonatal BCG vaccination was reported to improve neurogenesis in  
561 mice<sup>53</sup>.

562  
563 Moreover, baseline DNA methylation levels impact the cytokine changes following BCG  
564 vaccination in a sex-specific manner. We identified the dopaminergic neurogenesis pathway in  
565 females to influence the IFN- $\gamma$  associated CpG sites, which confirmed the importance of  
566 epigenetic modifications in the neuronal crosstalk with the immune system after BCG  
567 vaccination in females. We also revealed that the IFN- $\gamma$  associated CpG sites in males were

568 enriched in the receptor tyrosine kinases pathway, which was known as key regulators of an  
569 uncontrolled immune response and played a critical role in the control of autoimmune  
570 disorders<sup>54</sup>. Interestingly, we observed an association between IFN- $\gamma$  associated CpG sites and  
571 cortisol, specifically in females. Cortisol, a mediator of stress-induced immune-suppression,  
572 may affect both innate and adaptive immunity. A previous study revealed that infants with  
573 higher cortisol response to pain and lower delayed-type hypersensitivity response to BCG  
574 vaccination<sup>55</sup>.

575

576 This study has also some limitations that should be acknowledged. Firstly, it is important to  
577 note that DNA methylation is cell-type specific and cannot be assessed at single-cell resolution  
578 in this study. Secondly, the DNA methylation analysis conducted using the EPIC array only  
579 covers approximately 3% of the CpG sites in the genome. Finally, although we were able to  
580 partially replicate our results in an independent cohort, the validation study had limited  
581 statistical power due to the limited sample size.

582

583 In conclusion, our study provides valuable insights into the dynamic changes of DNA  
584 methylation following BCG vaccination and highlights the induction of immune-related  
585 epigenetic memory through these dynamic DNA methylation changes. The observed DNA  
586 methylation changes play a regulatory role in immunological responses triggered by BCG  
587 vaccination, underscoring the presence of immune-related epigenetic memory.

588

## 589 **Method**

### 590 ***Study design and cohort description***

591 In the 300BCG study, 303 healthy Dutch individuals were included from April 2017 until June  
592 2018. After obtaining the written informed consent, blood was collected, followed by the  
593 administration of a standard dose of 0.1 mL BCG (BCG-Bulgaria, InterVax) intradermally in  
594 the left upper arm by a medical doctor. Two weeks and 3 months after BCG vaccination,  
595 additional blood samples were collected and a questionnaire was completed. Exclusion criteria  
596 were the use of systemic medication other than oral contraceptives or acetaminophen, use of  
597 antibiotics 3 months before inclusion, previous BCG vaccination, history of tuberculosis, any  
598 febrile illness 4 weeks before participation, any vaccination 3 months before participation, or  
599 a medical history of immunodeficiency. This study was approved by the Arnhem-Nijmegen  
600 Medical Ethical Committee (NL58553.091.16).

601

### 602 ***DNA methylation measurement and quality control***

603 DNA was isolated from whole blood using a QIAamp blood kit (Qiagen Benelux BV, Venlo,  
604 the Netherlands) kit, and the concentration was determined using a NanoDrop  
605 spectrophotometer at 260 nm. Genome-wide DNA methylation profiles were measured by  
606 Infinium© MethylationEPIC array (~850,000 CpG sites). DNA methylation data were pre-  
607 processed in R (version 4.0) with the Bioconductor package Minfi<sup>56</sup>, using the original IDAT  
608 files extracted from the HiScanSQ scanner. We removed the samples which had bad call  
609 rate(n=4), sex-mismatched (n=1), and we checked whether had mixed-up samples by  
610 inspecting the correlation of the beta value for SNPs. Mismatched samples were replaced by a  
611 new label with a correlation of larger than 0.7. Quality control was performed to filter bad  
612 quality probes with a detection P-value>0.01, cross-reactive probes, polymorphic probes<sup>57,58</sup>,  
613 and probes in the sex chromosome. We subsequently implemented stratified quantile  
614 normalization<sup>59</sup>. Based on methylation value, cell proportion was estimated using Housman's  
615 method<sup>24</sup>. After quality control and matching with phenotype data, 284 samples and 751,564  
616 probes remained for further analyses. Methylation levels (beta values,  $\beta$ ) were converted into  
617 M values ( $\log_2(\beta/1-\beta)$ ), which were used in downstream differential methylation analyses.  
618 Extreme outliers in the methylation data were identified using the Tukey method ( $<1\text{st}$   
619 quartile $-3 \times \text{IQR}$ ;  $>3\text{rd}$  quartile $+3 \times \text{IQR}$ ) and set as missing.

620

### 621 ***Assessment of ex vivo cytokine responses***

622 Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA whole blood with  
623 Ficoll-Paque (GE Healthcare) density gradient separation. Cells were washed twice in PBS and  
624 suspended in RPMI culture medium (Roswell Park Memorial Institute medium, Invitrogen,  
625 CA, USA) supplemented with 50 mg/mL gentamicin (Centrafarm), 2 mM glutamax (GIBCO),  
626 and 1 mM pyruvate (GIBCO). Subsequently, the PBMCs were stimulated *ex vivo* with  $10^6$   
627 CFU/mL heat-killed *Staphylococcus aureus* or left unstimulated. Cytokine production of TNF-  
628  $\alpha$ , IL-6, and IL-1 $\beta$  was measured in 24-hour supernatants, and IFN- $\gamma$  was measured in  
629 supernatants 7 days after stimulation using ELISA. Then, we calculated the fold change in  
630 cytokine production (3 months after vaccination compared to baseline). After log<sub>10</sub>  
631 transformation and correcting for batch effect, the value was used as a measurement of the  
632 magnitude of the trained immunity response. For the *in-vitro* validation of the  
633 immunomodulatory role of kisspeptin, a similar 7-days stimulation assay for the production of  
634 IFN- $\gamma$  was employed in human PBMCs.

635

#### 636 ***Association of DNA methylation with BCG effect and immune responses***

637 Principle component analysis (PCA) was performed using DNA methylation data from each  
638 time point respectively. The top 30 PCs were associated with variables including age, sex,  
639 batch, BMI, smoking, and estimated cell counts by linear regression model.

640

641 To assess the DNA methylation changes induced by BCG vaccination, a linear mix effect  
642 model was performed for each CpG site, with time point as the independent variable, subject  
643 ID as the random effect, and age, sex, batch, and estimated cell counts as the covariates. Besides  
644 the overall changes, we also assessed the changes from T0 to T14, T0 to T90, and T14 to T90,  
645 using the same model which only included two time points. EWAS of trained *ex vivo* cytokine  
646 response at each time point was performed by fitting the robust linear regression model  
647 adjusting for age, sex, batch, and estimated cell counts. The *ex vivo* cytokine response was  
648 normalized by the inverse rank method. Besides, we also assessed the association between  
649 DNA methylation changes and *ex vivo* cytokine production changes using the robust linear  
650 regression model. Considering the different estimated cell counts at different time points, we  
651 first regress out the cell counts and batch at each time point from DNA methylation M values,  
652 and the residuals were obtained. Then we used a robust linear regression model to correlate the  
653 DNA methylation changes (differences in the residuals at any two time points T90-T0, T14-  
654 T0, and T90-T14), to the trained immunity response with age and gender as covariables. CpG



655 sites passed the threshold of  $FDR < 0.05$  were considered significant findings. The sex-stratified  
656 analysis was performed in male and female respectively using the same models mentioned  
657 above.

658  
659 The identified CpG sites were annotated to nearby genes by the GREAT annotation tool<sup>60</sup>. A  
660 tool called experimentally derived Functional element Overlap analysis of ReGions from  
661 EWAS (eFORGE) 2.0<sup>27</sup> was used to annotate the CpG sites associated with the BCG effect to  
662 further understand the function of these CpG sites in transcription activity. We applied this tool  
663 to methylated and demethylated CpG sites with P value  $< 10^{-5}$  respectively of the overall BCG  
664 model. Pathway analysis of genes mapped to identified CpG lists was performed with the  
665 online tool CPDB <http://cpdb.molgen.mpg.de/>. DNA methylation levels and estimated cell  
666 proportions at different time points (for 11 CpG sites associated with the overall BCG effect)  
667 were performed by Spearman correlation. Neutrophil cell counts were also measured by flow  
668 cytometry where the sub-cell types were also measured. And then the cell counts were  
669 correlated to 11 CpG sites by Spearman correlation.

670  
671 The assessment and quality control steps for inflammatory protein data were published  
672 previously<sup>9</sup>. Proteins that were significantly decreased at T14 compared to T0 (N=24), and T90  
673 compared to T0 (N=10) were selected based on the previous study<sup>9</sup>. CpG sites that were  
674 significantly changed at T14 compared to T0 (N=39), and T90 compared to T0 (N=36) were  
675 selected by previous steps in this study. The associations between DNA methylation changes  
676 (T14-T0 and T90-T0) and inflammatory protein changes (fold change T14/T0 and T90/T0)  
677 were performed by Spearman correlation.

### 678 679 ***Variance explanation***

680 We estimated the variance explained by age, sex, PRS, as well as DNA methylation,  
681 inflammatory proteins, and circulating metabolites at baseline, on *ex vivo* IFN- $\gamma$  response. The  
682 PRS was calculated from SNPs associated with the trained immune response. Inflammatory  
683 proteins at baseline were assessed by Olink inflammation panel<sup>9</sup>. Baseline metabolites were  
684 measured and annotated by the General Metabolics (Zurich, Switzerland) using flow injection  
685 time-of-flight mass (flow-injection TOF-M) spectrometry<sup>10</sup>.

686 We first select the features by associating the features in each data level to TI (IFN- $\gamma$ ). If a  
687 feature showed a significant association (Spearman correlation, P value  $< 0.05$ ), the feature was

688 included as the candidate predictor. For DNA methylation we included the 41 CpG sites  
689 identified by EWAS analysis. For metabolites data, we included 34 metabolites that were  
690 significantly associated with TI (IFN- $\gamma$ ,  $P < 0.05$ ). And for protein data, we do not identify any  
691 significant proteins that were associated with TI (IFN- $\gamma$ ). Each candidate predictor from each  
692 data layer was correlated to other predictors within the data layer to identify collinearity among  
693 these predictors. If the features within this layer showed an association (Spearman correlation  $>$   
694 0.4), the feature which showed the least association (based on the p-value) to TI (IFN- $\gamma$ ) was  
695 further removed from the candidate predictors. This yielded a unique set of predictors from  
696 each layer, which was then used to fit a multivariate linear model to estimate the variance  
697 explained by these features for TI (IFN- $\gamma$ ). Finally, 31 CpG sites and 23 metabolites were  
698 selected by these approaches and were used in the variance calculation. To account for the  
699 inflation that adding more predictors has on the explained variation, the adjusted  $R^2$  was used  
700 as the measure of explained variance. Additionally, we also randomly selected the same  
701 number of features ( $n=73$ , the number of proteins available in this study) 1000 times, and  
702 repeated the approaches mentioned above to get the variance explained by randomly selected  
703 features.

#### 704 ***Cytokine-QTL and enrichment analysis***

705 The association between SNP dosages and IFN- $\gamma$  responses (cytokine QTL) was done using  
706 Matrix eQTL R package<sup>61</sup> with the inversed rank normalized IFN- $\gamma$  responses value as the  
707 dependent factor, adjusting for age and sex. Using the identified IFN- $\gamma$  associated CpG sites  
708 list ( $N=41$ , [Table S13](#)), cytokine QTL p-values of those SNPs located 250 kb upstream or  
709 downstream of those CpG sites were extracted and plotted against random cytokine QTL p-  
710 values. By this, the *cis* effect of CpG sites on cytokine QTL was tested.

711

#### 712 ***Bi-directional mediation analysis***

713 Matrix eQTL<sup>61</sup> was used to identify the significant pairs of TI-SNPs and DNAm-C SNPs after  
714 regressing out age and gender. For SNPs significantly associated with both TI and DNAm-C  
715 ( $P < 0.05$ ), we carried out bi-directional mediation analysis ( $y = x + m + \epsilon$ , where  $y$  is the  
716 outcome,  $x$  is the SNP dosage and  $m$  represents the mediator) using mediation R package (ref  
717 mediation: R Package for Causal Mediation Analysis) to infer the mediation effect of TI or  
718 DNAm-C for genetic impacts.

719

#### 720 ***Replication cohort***

721 We replicated our results in a cohort consisting of 17 individuals from BCG booster cohort<sup>23</sup>.  
722 This randomized placebo-controlled trial originally compares different BCG vaccination  
723 regimens for identifying their efficacy to establish trained immunity. The 17 volunteers that  
724 received one dose of BCG as positive control were used as validation cohorts in the current  
725 study. Vaccination was performed intradermally in the left upper arm as the same manner as  
726 with the discovery cohort. Blood was drawn at baseline, and three months after the vaccination.  
727 The trial protocol was registered under NL58219.091.16 in the Dutch trial registry, and was  
728 approved in 2019 by the Arnhem-Nijmegen Ethics Committee. All experiments were  
729 conducted in accordance with the Declaration of Helsinki and no adverse events were recorded.

730

### 731 ***Data and code availability***

732 DNA methylation data have been deposited at the European Genome-phenome Archive (EGA),  
733 which is hosted by the EBI and the CRG, under accession number EGAS00001007498.  
734 Code generated to process the data are freely available on Github ([https://github.com/CiiM-](https://github.com/CiiM-Bioinformatics-group/BCG_methylation_project)  
735 [Bioinformatics-group/BCG\\_methylation\\_project](https://github.com/CiiM-Bioinformatics-group/BCG_methylation_project))

736

737

### 738 **Author Contributions**

739 MGN, CX and YL conceptualized and designed the study. CQ and ZL performed the data  
740 analysis supervised by YL, CX and MGN. SJCFMM and VACMK recruited the participants  
741 and collected the biological material. GK, ASS and PAD performed DNA isolation and  
742 supported the functional experiments; helped with participant recruitment and interpretation of  
743 the data, with support from AP, LCJdeB, VPM and LABJ. YAM, WL, MG, and AA helped  
744 with part of the data analysis. CQ, ZL, CX and MGN wrote the manuscript with input from all  
745 the authors. All authors reviewed and approved the manuscript.

746

747

### 748 **Acknowledgments**

749 YL was supported by an ERC starting Grant (948207) and a Radboud University Medical  
750 Centre Hypatia Grant (2018). CJX was supported by Helmholtz Initiative and Networking  
751 Fund (1800167) and Deutsche Forschungsgemeinschaft (DFG) Fund (497673685). MGN was  
752 supported by an ERC Advanced Grant (833247) and a Spinoza Grant of the Netherlands  
753 Organization for Scientific Research.

754

755

756 **References**

- 757 1. Netea, M.G., Quintin, J., and van der Meer, J.W.M. (2011). Trained immunity: a memory  
758 for innate host defense. *Cell Host Microbe* 9, 355–361. 10.1016/j.chom.2011.04.006.
- 759 2. Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A.B., Ifrim, D.C., Saeed, S., Jacobs,  
760 C., van Loenhout, J., de Jong, D., Stunnenberg, H.G., et al. (2012). Bacille Calmette-  
761 Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic  
762 reprogramming of monocytes. *Proc Natl Acad Sci U S A* 109, 17537–17542.  
763 10.1073/pnas.1202870109.
- 764 3. Arts, R.J.W., Moorlag, S.J.C.F.M., Novakovic, B., Li, Y., Wang, S.-Y., Oosting, M.,  
765 Kumar, V., Xavier, R.J., Wijmenga, C., Joosten, L.A.B., et al. (2018). BCG Vaccination  
766 Protects against Experimental Viral Infection in Humans through the Induction of  
767 Cytokines Associated with Trained Immunity. *Cell Host Microbe* 23, 89-100.e5.  
768 10.1016/j.chom.2017.12.010.
- 769 4. Giamarellos-Bourboulis, E.J., Tsilika, M., Moorlag, S., Antonakos, N., Kotsaki, A.,  
770 Domínguez-Andrés, J., Kyriazopoulou, E., Gkavogianni, T., Adami, M.-E., Damoraki,  
771 G., et al. (2020). Activate: Randomized Clinical Trial of BCG Vaccination against  
772 Infection in the Elderly. *Cell* 183, 315-323.e9. 10.1016/j.cell.2020.08.051.
- 773 5. Kaufmann, E., Khan, N., Tran, K.A., Ulndreaj, A., Pernet, E., Fontes, G., Lupien, A.,  
774 Desmeules, P., McIntosh, F., Abow, A., et al. (2022). BCG vaccination provides  
775 protection against IAV but not SARS-CoV-2. *Cell Rep* 38, 110502.  
776 10.1016/j.celrep.2022.110502.
- 777 6. Moorlag, S.J.C.F.M., Rodriguez-Rosales, Y.A., Gillard, J., Fanucchi, S., Theunissen, K.,  
778 Novakovic, B., de Bont, C.M., Negishi, Y., Fok, E.T., Kalafati, L., et al. (2020). BCG  
779 Vaccination Induces Long-Term Functional Reprogramming of Human Neutrophils. *Cell*  
780 *Rep* 33, 108387. 10.1016/j.celrep.2020.108387.
- 781 7. Netea, M.G., Joosten, L.A.B., Latz, E., Mills, K.H.G., Natoli, G., Stunnenberg, H.G.,  
782 O’Neill, L.A.J., and Xavier, R.J. (2016). Trained immunity: A program of innate immune  
783 memory in health and disease. *Science* 352, aaf1098. 10.1126/science.aaf1098.
- 784 8. Divangahi, M., Aaby, P., Khader, S.A., Barreiro, L.B., Bekkering, S., Chavakis, T., van  
785 Crevel, R., Curtis, N., DiNardo, A.R., Dominguez-Andres, J., et al. (2021). Trained  
786 immunity, tolerance, priming and differentiation: distinct immunological processes. *Nat*  
787 *Immunol* 22, 2–6. 10.1038/s41590-020-00845-6.
- 788 9. Koeken, V.A., de Bree, L.C.J., Mourits, V.P., Moorlag, S.J., Walk, J., Cirovic, B., Arts,  
789 R.J., Jaeger, M., Dijkstra, H., Lemmers, H., et al. (2020). BCG vaccination in humans  
790 inhibits systemic inflammation in a sex-dependent manner. *J Clin Invest* 130, 5591–5602.  
791 10.1172/JCI133935.
- 792 10. Koeken, V.A.C.M., Qi, C., Mourits, V.P., de Bree, L.C.J., Moorlag, S.J.C.F.M.,  
793 Sonawane, V., Lemmers, H., Dijkstra, H., Joosten, L.A.B., van Laarhoven, A., et al.  
794 (2022). Plasma metabolome predicts trained immunity responses after antituberculosis  
795 BCG vaccination. *PLoS Biol* 20, e3001765. 10.1371/journal.pbio.3001765.

- 796 11. Kong, L., Moorlag, S.J.C.F.M., Lefkovith, A., Li, B., Matzaraki, V., van Emst, L., Kang,  
797 H.A., Latorre, I., Jaeger, M., Joosten, L.A.B., et al. (2021). Single-cell transcriptomic  
798 profiles reveal changes associated with BCG-induced trained immunity and protective  
799 effects in circulating monocytes. *Cell Rep* 37, 110028. 10.1016/j.celrep.2021.110028.
- 800 12. Zhang, B., Moorlag, S.J., Dominguez-Andres, J., Bulut, Ö., Kilic, G., Liu, Z., van Crevel,  
801 R., Xu, C.-J., Joosten, L.A., Netea, M.G., et al. (2022). Single-cell RNA sequencing  
802 reveals induction of distinct trained-immunity programs in human monocytes. *J Clin*  
803 *Invest* 132, e147719. 10.1172/JCI147719.
- 804 13. Li, W., Moorlag, S.J.C.F.M., Koeken, V.A.C.M., Röring, R.J., de Bree, L.C.J., Mourits,  
805 V.P., Gupta, M.K., Zhang, B., Fu, J., Zhang, Z., et al. (2023). A single-cell view on host  
806 immune transcriptional response to in vivo BCG-induced trained immunity. *Cell Rep* 42,  
807 112487. 10.1016/j.celrep.2023.112487.
- 808 14. Stražar, M., Mourits, V.P., Koeken, V.A.C.M., de Bree, L.C.J., Moorlag, S.J.C.F.M.,  
809 Joosten, L.A.B., van Crevel, R., Vlamakis, H., Netea, M.G., and Xavier, R.J. (2021). The  
810 influence of the gut microbiome on BCG-induced trained immunity. *Genome Biol* 22,  
811 275. 10.1186/s13059-021-02482-0.
- 812 15. Pavan Kumar, N., Padmapriyadarsini, C., Rajamanickam, A., Marinaik, S.B., Nancy, A.,  
813 Padmanaban, S., Akbar, N., Murhekar, M., and Babu, S. (2021). Effect of BCG  
814 vaccination on proinflammatory responses in elderly individuals. *Sci Adv* 7, eabg7181.  
815 10.1126/sciadv.abg7181.
- 816 16. Fanucchi, S., Domínguez-Andrés, J., Joosten, L.A.B., Netea, M.G., and Mhlanga, M.M.  
817 (2021). The Intersection of Epigenetics and Metabolism in Trained Immunity. *Immunity*  
818 54, 32–43. 10.1016/j.immuni.2020.10.011.
- 819 17. Pacis, A., Tailleux, L., Morin, A.M., Lambourne, J., MacIsaac, J.L., Yotova, V.,  
820 Dumaine, A., Danckaert, A., Luca, F., Grenier, J.-C., et al. (2015). Bacterial infection  
821 remodels the DNA methylation landscape of human dendritic cells. *Genome Res* 25,  
822 1801–1811. 10.1101/gr.192005.115.
- 823 18. Gupta, M.K., Peng, H., Li, Y., and Xu, C.-J. (2023). The role of DNA methylation in  
824 personalized medicine for immune-related diseases. *Pharmacol Ther* 250, 108508.  
825 10.1016/j.pharmthera.2023.108508.
- 826 19. Pacis, A., Mailhot-Léonard, F., Tailleux, L., Randolph, H.E., Yotova, V., Dumaine, A.,  
827 Grenier, J.-C., and Barreiro, L.B. (2019). Gene activation precedes DNA demethylation  
828 in response to infection in human dendritic cells. *Proc. Natl. Acad. Sci. U.S.A.* 116,  
829 6938–6943. 10.1073/pnas.1814700116.
- 830 20. Bannister, S., Kim, B., Domínguez-Andrés, J., Kilic, G., Ansell, B.R.E., Neeland, M.R.,  
831 Moorlag, S.J.C.F.M., Matzaraki, V., Vlahos, A., Shepherd, R., et al. (2022). Neonatal  
832 BCG vaccination is associated with a long-term DNA methylation signature in  
833 circulating monocytes. *Sci Adv* 8, eabn4002. 10.1126/sciadv.abn4002.
- 834 21. Takahashi, H., Kühtreiber, W.M., Keefe, R.C., Lee, A.H., Aristarkhova, A., Dias, H.F.,  
835 Ng, N., Nelson, K.J., Bien, S., Scheffey, D., et al. (2022). BCG vaccinations drive

- 836 epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes.  
837 *Sci Adv* 8, eabq7240. 10.1126/sciadv.abq7240.
- 838 22. Verma, D., Parasa, V.R., Raffetseder, J., Martis, M., Mehta, R.B., Netea, M., and Lerm,  
839 M. (2017). Anti-mycobacterial activity correlates with altered DNA methylation pattern  
840 in immune cells from BCG-vaccinated subjects. *Sci Rep* 7, 12305. 10.1038/s41598-017-  
841 12110-2.
- 842 23. Debisarun, P.A., Kilic, G., de Bree, L.C.J., Pennings, L.J., van Ingen, J., Benn, C.S.,  
843 Aaby, P., Dijkstra, H., Lemmers, H., Domínguez-Andrés, J., et al. (2023). The impact of  
844 BCG dose and revaccination on trained immunity. *Clin Immunol* 246, 109208.  
845 10.1016/j.clim.2022.109208.
- 846 24. Houseman, E., Accomando, W.P., Koestler, D.C., Christensen, B.C., Marsit, C.J.,  
847 Nelson, H.H., Wiencke, J.K., and Kelsey, K.T. (2012). DNA methylation arrays as  
848 surrogate measures of cell mixture distribution. *BMC Bioinformatics* 13, 86.  
849 10.1186/1471-2105-13-86.
- 850 25. Li, Y.-L., Zhao, H., and Ren, X.-B. (2016). Relationship of VEGF/VEGFR with immune  
851 and cancer cells: staggering or forward? *Cancer Biol Med* 13, 206–214.  
852 10.20892/j.issn.2095-3941.2015.0070.
- 853 26. Chen, M.L., Ge, Z., Fox, J.G., and Schauer, D.B. (2006). Disruption of tight junctions  
854 and induction of proinflammatory cytokine responses in colonic epithelial cells by  
855 *Campylobacter jejuni*. *Infect Immun* 74, 6581–6589. 10.1128/IAI.00958-06.
- 856 27. Breeze, C.E., Reynolds, A.P., van Dongen, J., Dunham, I., Lazar, J., Neph, S., Vierstra,  
857 J., Bourque, G., Teschendorff, A.E., Stamatoyannopoulos, J.A., et al. (2019). eFORGE  
858 v2.0: updated analysis of cell type-specific signal in epigenomic data. *Bioinformatics* 35,  
859 4767–4769. 10.1093/bioinformatics/btz456.
- 860 28. Hernando-Herraez, I., Evano, B., Stubbs, T., Commere, P.-H., Jan Bonder, M., Clark, S.,  
861 Andrews, S., Tajbakhsh, S., and Reik, W. (2019). Ageing affects DNA methylation drift  
862 and transcriptional cell-to-cell variability in mouse muscle stem cells. *Nat Commun* 10,  
863 4361. 10.1038/s41467-019-12293-4.
- 864 29. Choi, S.W., Mak, T.S.-H., and O'Reilly, P.F. (2020). Tutorial: a guide to performing  
865 polygenic risk score analyses. *Nat Protoc* 15, 2759–2772. 10.1038/s41596-020-0353-1.
- 866 30. Huang, H., Xiong, Q., Wang, N., Chen, R., Ren, H., Siwko, S., Han, H., Liu, M., Qian,  
867 M., and Du, B. (2018). Kisspeptin/GPR54 signaling restricts antiviral innate immune  
868 response through regulating calcineurin phosphatase activity. *Sci Adv* 4, eaas9784.  
869 10.1126/sciadv.aas9784.
- 870 31. Wang, Z., Wu, J., Jiang, J., Ma, Q., Song, M., Xu, T., Liu, Y., Chen, Z., Bao, Y., Huang,  
871 M., et al. (2022). KIF2A decreases IL-33 production and attenuates allergic asthmatic  
872 inflammation. *Allergy Asthma Clin Immunol* 18, 55. 10.1186/s13223-022-00697-9.
- 873 32. de Vries, S., Benes, V., Naarmann-de Vries, I.S., Rücklé, C., Zarnack, K., Marx, G.,  
874 Ostareck, D.H., and Ostareck-Lederer, A. (2021). P23 Acts as Functional RBP in the  
875 Macrophage Inflammation Response. *Front Mol Biosci* 8, 625608.  
876 10.3389/fmolb.2021.625608.




- 877 33. Cheng, S.-C., Quintin, J., Cramer, R.A., Shepardson, K.M., Saeed, S., Kumar, V.,  
878 Giamarellos-Bourboulis, E.J., Martens, J.H.A., Rao, N.A., Aghajani-refah, A., et al.  
879 (2014). mTOR- and HIF-1 $\alpha$ -mediated aerobic glycolysis as metabolic basis for trained  
880 immunity. *Science* 345, 1250684. 10.1126/science.1250684.
- 881 34. Setoguchi, R., Matsui, Y., and Mouri, K. (2015). mTOR signaling promotes a robust and  
882 continuous production of IFN- $\gamma$  by human memory CD8<sup>+</sup> T cells and their proliferation.  
883 *Eur J Immunol* 45, 893–902. 10.1002/eji.201445086.
- 884 35. Tingley, D., Yamamoto, T., Hirose, K., Keele, L., and Imai, K. (2014). Mediation: R  
885 package for causal mediation analysis.
- 886 36. Wang, C., and Ruan, J. (2023). An ancient defense mechanism: Conservation of  
887 gasdermin-mediated pyroptosis. *PLoS Biol* 21, e3002103. 10.1371/journal.pbio.3002103.
- 888 37. Greenwood, C.S., Wynosky-Dolfi, M.A., Beal, A.M., and Booty, L.M. (2023).  
889 Gasdermins assemble; recent developments in bacteriology and pharmacology. *Front*  
890 *Immunol* 14, 1173519. 10.3389/fimmu.2023.1173519.
- 891 38. Cruz-Rangel, S., Melo, Z., Vázquez, N., Meade, P., Bobadilla, N.A., Pasantes-Morales,  
892 H., Gamba, G., and Mercado, A. (2011). Similar effects of all WNK3 variants on SLC12  
893 cotransporters. *Am J Physiol Cell Physiol* 301, C601-608. 10.1152/ajpcell.00070.2011.
- 894 39. Lam, B.Y.H., Williamson, A., Finer, S., Day, F.R., Tadross, J.A., Gonçalves Soares, A.,  
895 Wade, K., Sweeney, P., Bedenbaugh, M.N., Porter, D.T., et al. (2021). MC3R links  
896 nutritional state to childhood growth and the timing of puberty. *Nature* 599, 436–441.  
897 10.1038/s41586-021-04088-9.
- 898 40. Gumus, E. (2018). Case report of four siblings in southeast Turkey with a novel  
899 RAB3GAP2 splice site mutation: Warburg micro syndrome or Martsolf syndrome?  
900 *Ophthalmic Genet* 39, 391–395. 10.1080/13816810.2018.1432065.
- 901 41. Quintin, J., Saeed, S., Martens, J.H.A., Giamarellos-Bourboulis, E.J., Ifrim, D.C., Logie,  
902 C., Jacobs, L., Jansen, T., Kullberg, B.-J., Wijmenga, C., et al. (2012). *Candida albicans*  
903 infection affords protection against reinfection via functional reprogramming of  
904 monocytes. *Cell Host Microbe* 12, 223–232. 10.1016/j.chom.2012.06.006.
- 905 42. Saeed, S., Quintin, J., Kerstens, H.H.D., Rao, N.A., Aghajani-refah, A., Matarese, F.,  
906 Cheng, S.-C., Ratter, J., Berentsen, K., van der Ent, M.A., et al. (2014). Epigenetic  
907 programming of monocyte-to-macrophage differentiation and trained innate immunity.  
908 *Science* 345, 1251086. 10.1126/science.1251086.
- 909 43. Netea, M.G., Domínguez-Andrés, J., Barreiro, L.B., Chavakis, T., Divangahi, M., Fuchs,  
910 E., Joosten, L.A.B., van der Meer, J.W.M., Mhlanga, M.M., Mulder, W.J.M., et al.  
911 (2020). Defining trained immunity and its role in health and disease. *Nat Rev Immunol*  
912 20, 375–388. 10.1038/s41577-020-0285-6.
- 913 44. Unnikrishnan, A., Freeman, W.M., Jackson, J., Wren, J.D., Porter, H., and Richardson,  
914 A. (2019). The role of DNA methylation in epigenetics of aging. *Pharmacol Ther* 195,  
915 172–185. 10.1016/j.pharmthera.2018.11.001.

- 916 45. Das, J., Verma, D., Gustafsson, M., and Lerm, M. (2019). Identification of DNA  
917 methylation patterns predisposing for an efficient response to BCG vaccination in healthy  
918 BCG-naïve subjects. *Epigenetics* *14*, 589–601. 10.1080/15592294.2019.1603963.
- 919 46. Kleinnijenhuis, J., Quintin, J., Preijers, F., Benn, C.S., Joosten, L.A.B., Jacobs, C., van  
920 Loenhout, J., Xavier, R.J., Aaby, P., van der Meer, J.W.M., et al. (2014). Long-lasting  
921 effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained  
922 immunity. *J Innate Immun* *6*, 152–158. 10.1159/000355628.
- 923 47. Wang, D., Wu, Z., Zhao, C., Yang, X., Wei, H., Liu, M., Zhao, J., Qian, M., Li, Z., and  
924 Xiao, J. (2021). KP-10/Gpr54 attenuates rheumatic arthritis through inactivating NF-κB  
925 and MAPK signaling in macrophages. *Pharmacol Res* *171*, 105496.  
926 10.1016/j.phrs.2021.105496.
- 927 48. Watanabe, T., and Sato, K. (2020). Roles of the kisspeptin/GPR54 system in  
928 pathomechanisms of atherosclerosis. *Nutr Metab Cardiovasc Dis* *30*, 889–895.  
929 10.1016/j.numecd.2020.02.017.
- 930 49. Murphy, D.M., Mills, K.H.G., and Basdeo, S.A. (2021). The Effects of Trained Innate  
931 Immunity on T Cell Responses; Clinical Implications and Knowledge Gaps for Future  
932 Research. *Front Immunol* *12*, 706583. 10.3389/fimmu.2021.706583.
- 933 50. Stensballe, L.G., Nante, E., Jensen, I.P., Kofoed, P.-E., Poulsen, A., Jensen, H., Newport,  
934 M., Marchant, A., and Aaby, P. (2005). Acute lower respiratory tract infections and  
935 respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG  
936 vaccination for girls community based case-control study. *Vaccine* *23*, 1251–1257.  
937 10.1016/j.vaccine.2004.09.006.
- 938 51. Biering-Sørensen, S., Jensen, K.J., Monterio, I., Ravn, H., Aaby, P., and Benn, C.S.  
939 (2018). Rapid Protective Effects of Early BCG on Neonatal Mortality Among Low Birth  
940 Weight Boys: Observations From Randomized Trials. *J Infect Dis* *217*, 759–766.  
941 10.1093/infdis/jix612.
- 942 52. Zakharova, L., Sharova, V., and Izvolskaia, M. (2020). Mechanisms of Reciprocal  
943 Regulation of Gonadotropin-Releasing Hormone (GnRH)-Producing and Immune  
944 Systems: The Role of GnRH, Cytokines and Their Receptors in Early Ontogenesis in  
945 Normal and Pathological Conditions. *Int J Mol Sci* *22*, 114. 10.3390/ijms22010114.
- 946 53. Yang, J., Qi, F., Gu, H., Zou, J., Yang, Y., Yuan, Q., and Yao, Z. (2016). Neonatal BCG  
947 vaccination of mice improves neurogenesis and behavior in early life. *Brain Res Bull*  
948 *120*, 25–33. 10.1016/j.brainresbull.2015.10.012.
- 949 54. Nag, K., and Chaudhary, A. (2009). Mediators of Tyrosine Phosphorylation in Innate  
950 Immunity: From Host Defense to Inflammation onto Oncogenesis. *Curr Signal Transduct*  
951 *Ther* *4*, 76–81. 10.2174/15743620978816750.
- 952 55. Huda, M.N., Ahmad, S.M., Alam, M.J., Khanam, A., Afsar, M.N.A., Wagatsuma, Y.,  
953 Raqib, R., Stephensen, C.B., and Laugero, K.D. (2019). Infant cortisol stress-response is  
954 associated with thymic function and vaccine response. *Stress* *22*, 36–43.  
955 10.1080/10253890.2018.1484445.

- 956 56. Aryee, M.J., Jaffe, A.E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A.P., Hansen,  
957 K.D., and Irizarry, R.A. (2014). Minfi: a flexible and comprehensive Bioconductor  
958 package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* 30,  
959 1363–1369. 10.1093/bioinformatics/btu049.
- 960 57. Pidsley, R., Zotenko, E., Peters, T.J., Lawrence, M.G., Risbridger, G.P., Molloy, P., Van  
961 Djik, S., Muhlhausler, B., Stirzaker, C., and Clark, S.J. (2016). Critical evaluation of the  
962 Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation  
963 profiling. *Genome Biol* 17, 208. 10.1186/s13059-016-1066-1.
- 964 58. Zhou, W., Laird, P.W., and Shen, H. (2017). Comprehensive characterization, annotation  
965 and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res*  
966 45, e22. 10.1093/nar/gkw967.
- 967 59. Touleimat, N., and Tost, J. (2012). Complete pipeline for Infinium(®) Human  
968 Methylation 450K BeadChip data processing using subset quantile normalization for  
969 accurate DNA methylation estimation. *Epigenomics* 4, 325–341. 10.2217/epi.12.21.
- 970 60. McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schaar, B.T., Lowe, C.B., Wenger,  
971 A.M., and Bejerano, G. (2010). GREAT improves functional interpretation of cis-  
972 regulatory regions. *Nature Biotechnology* 28, 495–501. 10.1038/nbt.1630.
- 973 61. Shabalin, A.A. (2012). Matrix eQTL: ultra fast eQTL analysis via large matrix  
974 operations. *Bioinformatics* 28, 1353–1358. 10.1093/bioinformatics/bts163.
- 975


976 **Figures**



977

978 **Figure 1 Study Design and data exploration.**

979 (A) Overview of the study design. (B) Main analysis in this study. (C) Heatmap of association  
 980 between covariates, estimated cell proportions and DNA methylation at T0, which are  
 981 represented as the top 30 PCs, capturing 35% of the variance. The association was performed  
 982 with univariable linear regression model, different colors in the figure indicate different level  
 983 of significance. BCG, Bacillus Calmette–Guérin; PC, principal component.




984

985 **Figure 2 BCG vaccine induced short-term and long-term methylation changes**

986 (A) Manhattan plot showing DNA methylation changes over time after BCG vaccination.  
987 Differentially methylated CpG sites (N=11) with false discovery rate (FDR) < 0.05, were  
988 highlighted and labeled with the probeID. (B) Heatmap of hierarchical clustering on changes  
989 of identified 11 CpG sites at T14 and T90 compared to T0, which are represented as the  
990 differences in DNA methylation beta values. (C) Bar plot of the number of CpG sites with

991 significant change over time with  $P < 1 \times 10^{-5}$  in different groups. Down\_down group indicates  
992 DNA methylation was decreased at both T14 and T90 compared with T0, similarly, down\_up,  
993 decreased at T14 and increased at T90, up\_down, increased at T14 and decreased at T90, and  
994 up\_up, increased at both T14 and T90. (D-F) Change patterns and pathway enrichment analysis  
995 of CpG sites identified which assessed the DNA methylation changes at day14 and day0 (T14-  
996 T0, D), day90 and day0 (T90-T0, E), as well as day90 and day14 (T90-T14, F) with  $P < 1 \times 10^{-}$   
997 5. Each panel includes line charts showing the patterns of changes with two plots showing  
998 decrease (upper) and increase (lower) change, respectively, and the top enriched pathways and  
999 chromatin state were labeled right to each line chart. The pathway enrichment analyses were  
1000 performed by CPDB (<http://cpdb.molgen.mpg.de/>) an online tool of gene set analysis, the  
1001 chromatin enrichment analysis was performed by eFORGE (<https://eforge.altiusinstitute.org/>).  
1002 (G) Bar plot showing the number of decreased and increased CpG sites identified from T14-  
1003 T0, T90-T0 and T90-T14, respectively. Blue represents hypomethylated sites and yellow  
1004 represents hypermethylated sites. The P value on the top of the figure showing the enrichment  
1005 hypomethylated/hypermethylated sites in increase/decrease status (Fisher's exact test).  
1006






1007

1008 **Figure 3. Baseline epigenetic markers and ex-vivo cytokine production changes**

1009 (A) Manhattan plot showing the association of baseline DNA methylation level and ex-vivo  
 1010 immune response, represented by fold-change of TNF- $\alpha$ , IL-1 $\beta$ , IL6 and IFN- $\gamma$  production  
 1011 stimulated by *S-aureus* 90 days after BCG vaccination compared to baseline (from middle to  
 1012 outside). Genome-wide significant CpG sites (FDR<0.05) are highlighted by red. (B) Bar plot  
 1013 showing the variation in *ex vivo* IFN- $\gamma$  response explained by data from various omics layers,  
 1014 including general information (age and sex), genetics (PRS), baseline DNA methylation,  
 1015 baseline inflammatory proteins, and baseline plasma metabolites. (C) Experimental validation.  
 1016 Chr: chromosome; AUC: area under the curve; CI confidence interval. PRS: polygenic risk  
 1017 score; DNA methylation: DNA methylation; protein: inflammatory proteins.

1018



1019

1020

**Figure 4. Causal relationship inference by bidirectional mediation analysis**

1021

(A) Framework of bidirectional mediation analysis between SNPs, DNA methylation changes

1022

(DNAm-C) and cytokine production changes (TI).

1023

(B) Number of CpG sites that were significant in mediation results of Direction1 (from DNAm-C to TI), Direction2 (from TI to

1024

DNAm-C) and both, for IFN- $\gamma$  (left) and IL-1 $\beta$  (right).

1025

(C) Sankey diagram showing the inferred causal relationship network of Direction1 with mediation P value <0.05.

1026


Example of causal relationships between SNP, DNAm-C and TI inferred by bidirectional

1027

mediation analysis. The beta coefficient and significance are labeled at each edge and the

1028

proportions of mediation effect are labeled at the center of ring charts. See also [Table S14](#).




1029

1030 **Figure 5. Sex-specific effect on BCG vaccination and the association with ex-vivo cytokine**  
1031 **production changes**

1032 (A) Miami plot showing the short-term DNA methylation changes upon BCG vaccination  
1033 (T14-T0) in females (upper) and males (lower). CpG sites with  $P < 1 \times 10^{-5}$  were highlighted by  
1034 red (female) and blue (male). (B) Scatter plot showing the consistency of results from males  
1035 and females regarding the short-term effect. The x-axis represents the  $-\log_{10}$  P value with the

1036 sign of change direction in females, and the y-axis showing the same value in males. The dots  
 1037 are significant CpG sites identified from female (red dots) and male (blue dots) respectively  
 1038 with  $P < 1 \times 10^{-5}$ . (C) Miami plot showing the long-term DNA methylation changes upon BCG  
 1039 vaccination (T90-T0) in females (upper) and males (lower), the only CpG site passed FDR  
 1040 significance was highlighted by green. (D) Scatter plot showing the consistency of results from  
 1041 males and females regarding the long-term effect. (E-F) Dot plot showing the pathway  
 1042 enrichment of genes annotated to the identified CpG sites in short-term (E) and long-term (F),  
 1043 with two panels for females (left) and males (left) respectively. (G) Miami plot showing the  
 1044 association between baseline DNA methylation and *ex vivo* production changes of IFN- $\gamma$  in  
 1045 females (upper) and males (lower) with  $FDR < 0.05$ . (H) Scatter plot showing the consistency  
 1046 of the results from G in males and females. The x-axis represents the  $-\log_{10} P$  value with the  
 1047 sign of correlation coefficient in females, and the y-axis showing the same value in males. (I)  
 1048 Heatmap showing the spearman correlation between TI (IFN- $\gamma$ ) associated CpG sites and  
 1049 baseline Hormone levels of androstenedione (ADNC), cortisol (CORC) and 11 deoxy cortisol  
 1050 (DESC). Only significant correlations ( $FDR < 0.05$ ) are shown in this heatmap. Cell colors  
 1051 indicate the  $-\log_{10}(P)$  with the sign of correlation coefficient of spearman correlation ( $\rho$ ),  
 1052 and the asterisks indicate the significance of the correlation (\*  $FDR < 0.05$ , \*\*  $FDR < 0.01$ ).  
 1053



1054  
 1055 **Figure 6. Summary of findings of this study**  
 1056